Understanding immune development to the COVID-19 virus (SARS-CoV-2) in areas of high malaria transmission will inform future COVID-19 control strategies and underlying immune development.
Despite initial fears, the COVID-19 pandemic's impact in many countries in Africa has been less serious than anticipated. Possible reasons for this relative protection from the COVID-19 virus include prior or current malaria infection, or other host factors like worm co-infection.
This project uses human clinical samples collected from a United States National Institutes of Health-funded observational study to investigate immune response to SARS-CoV-2 infection and vaccination in people in Malawi. T and B cell responses during and following infection and vaccination will be assessed in a large cohort of individuals. Responses will be compared to adults in Australia, and we'll assess the impact of host co-infections assess.
This project will use human clinical samples collected from an NIH funded observational study to investigate immune response to SARS-CoV-2 infection and vaccination in Malawians. T and B cell responses during and following infection and vaccination will be assessed in a large cohort of individuals. Responses will be compared to Australian adults and the impact of host co-infections assessed. You will learn to apply advanced immunology techniques (for example multiparametric flow cytometry, RNAseq, multi-omic analysis), and analyse data using bioinformatic pipelines, and advanced statistical methods.
Understanding immune development to SARS-CoV-2 in the context of areas of high malaria transmission will inform future COVID-19 control strategies and underlying immune development.
1